Cathy Yarbrough

Cathy Yarbrough

For over 25 years, Cathy Yarbrough has written about biomedical research and medical care as a journalist for The Atlanta Constitution, Kidney News, and DocGuide and as a communications strategist for Rockefeller University, Singapore's Biopolis and Fusionopolis, the American Society for Cell Biology and other leading research organizations. She is a member of the National Association of Science Writers.

ARTICLES BY CATHY YARBROUGH`

  • Why Pet Health Is The Focus Of A New Biotech Sector
    Why Pet Health Is The Focus Of A New Biotech Sector

    For Aratana Therapeutics, 2016 was a banner year. The biotech company, founded in 2010, achieved FDA approvals for three of its 10 pipeline drugs. Last year the Kansas City-based company also forged a global partnership with the pharmaceutical giant Eli Lilly, a track record that any young biotech company would like to achieve.

  • Why An Investment Banker Returned To Drug Development

    Sandesh Seth was not considering leaving his position as head of healthcare investment banking at Laidlaw & Co. U.K. Ltd, when the board of small-cap biotech Actinium Pharmaceuticals asked him last year to serve as the company’s executive chairman.

  • Why Animal Health Is The Next Big Growth Area
    Why Animal Health Is The Next Big Growth Area

    Executives from Merial (the animal health division of Sanofi) and Zoetis discuss why the financial community is considering the animal health industry a promising short- and long-term investment opportunity.

  • Millennials Are Hard-Working And Dedicated. Really, They Are!
    Millennials Are Hard-Working And Dedicated. Really, They Are!

    Millennials, the single largest demographic in the workplace today, are often derided as lazy, disrespectful, and needy. They’re also criticized as being so addicted to technology that they email and text message information that should be communicated face-to-face to supervisors and coworkers.

  • Why Now Is The Time For Pharma To Expand Into Africa
    Why Now Is The Time For Pharma To Expand Into Africa

    “GSK is willing to make a small return now because we have a long-term view of the market potential of Africa,” says Allan Pamba, M.D., GSK’s VP of pharmaceuticals for East Africa and VP for government affairs for Africa.

  • From Windowless Data Room To The CEO’s Office
    From Windowless Data Room To The CEO’s Office

    Kurt Graves, the 47-year-old chairman, president, and CEO of Boston-based Intarcia Therapeutics, got his first major break in the life sciences industry 25 years ago as a sales representative for Merck in his home state of Michigan.

  • A Life Sciences Start-Up Learns To Pivot And Overcome Adversity
    A Life Sciences Start-Up Learns To Pivot And Overcome Adversity

    Jonathan Lim, M.D., was only 31 years old when he was appointed Halozyme Therapeutics’ first president and CEO in 2003. During the previous two years, he was a management consultant at McKinsey & Company, advising C-suite executives of both start-ups and Fortune 500 companies in the healthcare industry. But, prior to Halozyme, which is headquartered in San Diego, Lim had not worked at a biotech or pharmaceutical company.

  • Search For New Therapeutic Targets Turns To “Loss-Of- Function” DNA Variants
    Search For New Therapeutic Targets Turns To “Loss-Of- Function” DNA Variants

    Fifteen years ago at a White House ceremony announcing the completion of the Human Genome Project’s draft of the human DNA sequence, President Bill Clinton told the audience of industry and academic leaders, government officials, and journalists that “today’s historic achievement is only a starting point. There is much hard work yet to be done.”

  • How BARDA Is Helping Speed Up Drug Development/Manufacture
    How BARDA Is Helping Speed Up Drug Development/Manufacture

    An unusual federal government agency, the Biomedical Advanced Research and Development Authority (BARDA), is providing funding and technical expertise to more than 85 pharmaceutical and biotech companies and 25 academic organizations.

  • Patient-Focused Drug Development: To Understand Patients, You Must Engage Them
    Patient-Focused Drug Development: To Understand Patients, You Must Engage Them

    When National Health Council (NHC) official Marc Boutin, J.D., speaks to an audience of pharmaceutical company executives about patient-focused drug development, he underscores the topic’s importance to the life sciences industry by stating, “Look at the person sitting on your right. Now, look at the person sitting on your left. One of them likely will be unemployed in five years.”

More From Cathy Yarbrough`